Is retatrutide FDA approved?

No, retatrutide is not yet FDA approved. It is currently in Phase 3 clinical trials conducted by Eli Lilly. The earliest potential FDA approval would be 2026-2027, depending on trial outcomes and the regulatory review process.

When will retatrutide be available?

Retatrutide availability depends on successful completion of Phase 3 trials and FDA approval. Based on current timelines, commercial availability in the United States could occur in late 2026 or 2027. Some patients may access it earlier through clinical trial enrollment.

Can I buy retatrutide now?

Retatrutide is not legally available for purchase as it hasn

How does retatrutide compare to approved GLP-1s?

In Phase 2 trials, retatrutide showed approximately 24% weight loss at the highest dose over 48 weeks—potentially superior to currently approved options like semaglutide (15-17%) and tirzepatide (20-22%). However, Phase 3 results are needed to confirm these findings.

Can I join a retatrutide clinical trial?

Yes, enrollment may be available for ongoing Phase 3 trials. You can search ClinicalTrials.gov for

PeptideKey Research Library

GLP-1 Triple Agonist: How Retatrutide Boosts GH 350%

Stay informed on Retatrutide availability for your research projects. Get updates on supply, sourcing, and ensure you have reliable access to this GLP-1 peptide. Verified info.

This research guide is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.